|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: Targeted Therapy Cancer Brands - High Growth Market will see Eight New Blockbusters by 2017
Datamonitor, July 2008, Pages: 272
Targeted therapies are the top selling class of cancer drug, reaching sales of nearly $15 billion in the seven major pharmaceutical markets in 2007. The high growth of this therapy class makes it attractive to drug developers, resulting in 10 new entrants to the market since 2005. More drugs are likely to gain approval in the near future, contributing to a rapidly changing competitive landscape.
Scope
- Forecast sales of every marketed targeted therapy cancer brand in each of the seven major markets over the period 2007 to 2017
- Analysis and segmentation of the market at various levels including drug class, indication, company and mode of administration
- Comprehensive brand profiles and analysis, including approval dates, patent expiries and all key events likely to impact sales
- Snapshot of the targeted therapy cancer brands market in the rest of the world
Highlights of this title
The targeted therapy cancer brands market is rapidly expanding and is forecast to maintain a high growth rate over the forecast period. The market will reach a value of over $42 billion by 2017 in the seven major pharmaceutical markets, growing at a CAGR of 11%
Approvals in new tumor types with high unmet need, use in earlier treatment settings and growing physician familiarity are among the factors likely to drive sales of the best performing targeted therapy brands. However, pharmacoeconomic pressures and the launch of generic and pipeline competitors will dampen the growth of certain brands
Monoclonal antibody targeted therapy cancer brands achieved higher sales than small molecule agents in 2007 and will remain the leading class over the forecast period. This is driven by the considerable success of the monoclonal antibody brands Avastin, Herceptin and Rituxan
Key reasons to purchase this title
- Quantify the performance of each of the marketed targeted therapy cancer brands in the seven major markets over the period 2007 to 2017
- Assess the changing key opportunities and threats both for currently marketed and pipeline targeted therapy cancer brands
- Identify the leading brands in this market over the next 10 years and understand the key factors driving their success
Customers who bought this item also bought
Antihormonal Therapy Cancer Brands - Careful Lifecycle Management Needed to Preserve Brand Dominance
Forecast Insight: Top 20 Cancer Therapy Brands
Commercial Insight: Top 20 Cancer Therapy Brands - Sales of targeted therapies overtake cytotoxics in 2006
Commercial Insight: Cytotoxic Therapy Cancer Brands - Looming Patent Expiries Limit Market Growth
Top 20 Therapy Cancer Brands - Key Brands Set to Consolidate Advantage as Competition Intensifies
Pipeline Insight: Molecular Targeted Cancer Therapies - More Pipeline Activity, Less Product Differentiation
Pipeline Insight: Molecular Targeted Cancer Therapies: Can Anything Else Revolutionize the Market?
Forecast Insight: Depression - Generic Induced Brand Erosion Leads to Market Decline
Stakeholder Insight: Renal Cancer - Targeted therapies rapidly take hold of market
Gastric Cancer - Targeted Therapies Compete for First-to-Market Status
The Cancer Market Outlook to 2012
Innovative and Targeted Cancer Therapies: Key Technologies, New Applications and Leading Players
|
|
|
|
